Norwegian health authorities are updating guidelines regarding prostate cancer screening, focusing on informed patient choice. Currently, there is no national, organized screening program for prostate cancer in Norway. The updated recommendations emphasize shared decision-making between doctors and men, particularly those over 50, regarding the potential benefits and harms of prostate-specific antigen (PSA) testing. Concerns exist about overdiagnosis and overtreatment associated with PSA testing, leading to unnecessary anxiety and procedures. The guidelines acknowledge that early detection can improve outcomes for aggressive cancers, but also highlight the risks of detecting slow-growing cancers that may never cause harm. The aim is to empower men to make informed decisions based on their individual risk factors and preferences, alongside medical advice. These changes reflect a broader international trend towards personalized approaches to cancer screening.